STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
RegulatoryapprovedPositive
AI Analysis
Summary
Regeneron won U.S. regulatory approval for a rare disease drug that prevents abnormal bone growth, marking the conclusion of a three-decade development effort.
Outcome Details
U.S. regulatory approval for Regeneron rare disease drug
Importance:8/10
Sentiment:
0.80
FDA approvalrare diseaseRegeneronheterotopic ossificationregulatory
Read the original article
Published by STAT News on August 20, 2026 1:01 PM